estrogen receptor binding site associated antigen 9Genealiases: EB9 · PDAF
Q-omics provides the consensus-scored EBAG9 profile across patient tissues and cancer cell-line models. EBAG9 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EBAG9 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, EBAG9 RNA expression shows 19,387 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where EBAG9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EBAG9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EBAG9 survival associations across molecular data types. EBAG9 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EBAG9 RNA expression–survival associations across cancer types. High EBAG9 expression shows unfavorable associations in UVM, KIRP and HNSC, but favorable associations in KIRC, MESO and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EBAG9 RNA expression.
This table summarizes EBAG9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for EBAG9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EBAG9 shows lower tumor expression in THCA and LUAD and higher tumor expression in KIRC, HNSC, LIHC and STAD. The THCA box plot shows higher EBAG9 RNA expression in normal versus tumor tissue (log2 FC = −1.430, t-test p < 0.001).
This table shows molecular features associated with EBAG9 in patient tissues and cancer cell lines. In patient samples, EBAG9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, EBAG9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
